Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2421
Fax+1 415-353-2467
Dr. Damon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1982 - 1985
University of Michigan Medical SchoolClass of 1982
Certifications & Licensure
CA State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma Start of enrollment: 2001 Jun 01
- Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).Brian A Jonas, Samantha C Fisch, Peter T Curtin, Gary J Schiller, Deepa Jeyakumar
Leukemia Research. 2025-06-02 - Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng
Leukemia & Lymphoma. 2025-05-07 - CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2025-04-01
Abstracts/Posters
- Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative NeoplasmsLloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...Lloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
BiTEs, CAR T-cell Therapy Enhance ALL Armamentarium, but Questions RemainJanuary 22nd, 2020
OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 19th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
